Podcasts about Clinical research

In today's episode of OncLive On Air®, Jonathan Trent, MD, PhD, and Neeta Somaiah, MD, sat down to discuss the evolving role of circulating tumor DNA (ctDNA) testing in gastrointestinal stromal tumors (GIST), as well as the importance of identifying both initial drivers of disease and secondary resistance mechanisms when approaching frontline treatment selection and overall therapeutic sequencing.Trent is a professor of medicine, associate director of Clinical Research, and director of the Sarcoma Medical Research Program at the University of Miami Miller School of Medicine, in Florida. Somaiah is a professor and chair of the Department of Sarcoma Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.Drs Trent and Somaiah began their discussion by highlighting the rarity of GIST, underscoring the importance of evaluation at specialized sarcoma centers and comprehensive molecular testing to identify driver alterations.Somaiah then reviewed the molecular landscape of GIST, noting that approximately 70% to 80% of tumors harbor activating mutations in the KIT gene, while additional cases involve rarer alterations such as BRAF or NTRK fusions. Of note, resistance to imatinib (Gleevec) frequently emerges through secondary mutations in KIT exons 13 or 17, which can influence sensitivity to subsequent TKIs.ctDNA testing may help detect these resistance mechanisms, particularly at progression or when tissue is limited, enabling clinicians to refine sequencing strategies, both experts explained. They also discussed how mutation-informed approaches may guide treatment selection, including emerging strategies such as combining sunitinib (Sutent) with bezuclastinib to address resistant clones involving KIT exon 13 or 17 alterations.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Get More Resources To Manifest A Life You Don't Need A Vacation From HERE Today's guest, Dr. Helané Wahbeh is the Director of Research at the Institute of Noetic Sciences, and a former president and current board member of the Parapsychological Association. Dr. Wahbeh is trained as a naturopathic physician and holds a Master of Clinical Research along with two post-doctoral research fellowships. She has published and spoken internationally about her studies on complementary and alternative medicine, mind-body medicine, extended human capacities, stress, post-traumatic stress disorder, and their relationships to physiology, health, and healing. Dr. Wahbeh is particularly recognized for her research on channeling and her noetic approach to it. For more information on the research discussed on this episode, go to www.noetic.org Learn more about your ad choices. Visit megaphone.fm/adchoices

Hear leading dermatologist Dr. E. James Song and patient advocate Ana Rinck share their perspectives on the use of biosimilars to manage psoriasis and psoriatic arthritis. The use of biosimilars is growing with 24 currently on the market and more on the way for the treatment of psoriasis and psoriatic arthritis. What does this mean for you? Find out as we explore the use of biosimilars, the impact of interchangeability, what it's like switching to a biosimilar, and what questions to ask your health care provider with leading dermatologist and NPF Medical Board member Dr. E. James Song, Director of Clinical Research at Frontier Dermatology Partners, and patient advocate Ana Rinck who currently uses a biosimilar to treat her psoriasis and psoriatic arthritis.   The intent of this episode is to offer an update on the use of biosimilars and to hear the experience of those who have used biosimilars to manage psoriatic disease. This episode is sponsored by Organon. Timestamps: (0:00) Intro to Psoriasis Uncovered and guest welcome to dermatologist Dr. E. James Song, Director of Clinical Research and Co-Chief Medical Officer, Frontier Dermatology, and patient advocate Ana Rinck, who presents her experience with using a biosimilar to treat psoriasis and psoriatic arthritis.  (0:58) Definition of what is a biosimilar in comparison to a biologic which is also referred to as the original bio-originator or reference product.   (3:10) What biosimilars are available and how they are used. (4:35) The term interchangeable and what it means for use of a biosimilar. (5:46) Ana's diagnosis to treatment options starting with use of topicals to ultimately use of a biosimilar.  (7:57) Treatment discussion and choices when faced with diminishing effectiveness within a class of medications. Should a biosimilar be considered as an option?                                                                                                                                                                (9:50) Questions to consider when there's a change in treatment. (10:57) FDA announcement to simplify the development process for biosimilars and what that means for the future use of biosimilars. (13:55) What to consider when thinking of a biosimilar as a treatment option and where to find help when needed.     (14:53) The hope and equity of access that biosimilars represent is here for the appropriate individual. Key Takeaways: ·       A biosimilar is an FDA-approved biologic product that behaves and functions like a brand biologic treatment which is also called the reference product or bio-originator. There are no clinically meaningful differences between biosimilars and their reference product.  ·       The FDA has approved several biosimilars for the treatment of psoriasis and psoriatic arthritis. Some have been identified as interchangeable which means a biosimilar could be substituted for a reference product without a health care provider's approval pending state legislative rules.    ·       Don't be afraid to ask questions or access resources to assist with preparing for a medication change should that change be initiated either by yourself, your healthcare provider, or your health insurance company.    Guest Bios:   E. James Song, M.D. is a nationally recognized dermatologist and clinical researcher who is also a Clinical Instructor at the University of Washington. Dr Song is recognized as a key opinion leader in treating psoriasis and atopic dermatitis. He is actively involved in the development of new therapies for dermatologic disease and has firsthand experience with treatments before they come to market. Dr. Song has been published extensively in peer review journals and regularly participates in meetings both as a lecturer and attendee.  He is also a Medical Board member of the National Psoriasis Foundation. He believes that the best health outcomes come from shared decision making between the patient and physician. Dr. Song strives to help patients understand not only their condition, but all their treatment options.  Ana Rinck is a patient advocate and volunteer for the National Psoriasis Foundation. She developed psoriasis in 2009 following symptoms she noticed for a few years which proved to be challenging to diagnose. She managed for many years on topicals and intralesional injections. In 2018 she was diagnosed with psoriatic arthritis and started use of a biologic realizing she needed to protect her joints from further damage. She now uses a biosimilar to manage her psoriatic disease. Ana owns her own private consulting business and is an Operations and Project Manager.  Resources: -Learn more about biosimilars, interchangeability, and state substitution rules.   -Armstrong A, Callis Duffin K, Feldman S, Glick B, Kalb R, Reddy S, Schwartzman S, Yamauchi P, Calabrese C, Cordoro K, Desai S, Gladman D, Han G, Hawkes JE, Hsu S, Kircik L, Koo J, Kreuger GG, Lebwohl M, Leonardi C, Lewitt GM, Liao W, Liu C, Markenson J, Merola JF, Orbai A, Prussick R, Richardson V, Soung J, Van Voorhees AS, Wallace E, Weinberg J, Wine Lee L, Harris J, Koons S, Howard L. Position Statement on the Use of Biosimilars for Psoriasis and Psoriatic Arthritis. National Psoriasis Foundation Medical Board. 2023. -If you need help finding a dermatologist near you contact the NPF's Patient Navigation Center for assistance.   

Hannah's LinkedIn: https://www.linkedin.com/in/hannahkempski/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Join Tremaine Grant, CEO of Pulse Intelligence Labs and Principal Engineer in Clinical Research, for a fascinating breakdown of the "Science of Strength." Using the global anime phenomenon Solo Leveling as a blueprint, Tremaine reveals how the show's leveling mechanics almost perfectly mirror the way the human body adapts to physical stress. In this episode, we move beyond the myth of "motivation" to explore the "system"—leveraging AI, wearable data, and clinical research to build an adaptive fitness framework that turns real human movement into intelligent growth.

Jaime: https://www.linkedin.com/in/jaime-valles-2a1728221/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Send a textDr. Michael Koren joins Kevin Geddings to contrast the fragmented NBC coverage of the Winter Olympics to the more comprehensive level of attention and care granted by clinical research staff. The doctor expresses woe at the lack of a national "moment" that should have been granted by back-to-back men's and women's hockey victories, caused by weak broadcast coverage. Dr. Koren gives a preview of current and upcoming clinical research studies in the pipeline and explains that research staff dive deep into each participant's individual circumstances, medical history, and needs to make sure the science and the participant receive the attention needed for a good trial and a good participant experience.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Episode 79 - Clinical Research Pearls and Pitfalls by AABIP

→ My one stop shop for quality supplements: https://theswellscore.com/pages/drg Episode Description If coffee isn't cutting it anymore—and you're exhausted but still can't sleep—this episode is for you. That "wired but tired" feeling isn't a sleep problem or even a stress problem. It's your HPA axis stuck in overdrive. Your body can't tell the difference between a work deadline and a life-threatening emergency, so your stress response never shuts off. The supplement industry knows you're burned out. That's why they're pushing adrenal cocktails, proprietary blends with pixie dust dosing, and adaptogens stacks with zero human research behind them. Dr. Christian Gonzalez cut through the noise to find the five most clinically validated adaptogens—herbs proven in randomized controlled trials to actually restore your stress response. In this episode, Dr. G breaks down: • The adaptogen that reduced cortisol by 27% in a meta-analysis of 25 human trials • Which Soviet-era herb improved VO2 max and is still used by athletes today • The "Queen of Herbs" that lowered inflammatory markers by 28% in stressed adults • Why one popular adaptogen might cause emotional flatness in certain people—and who should avoid it • The Arctic root that pulled people out of burnout in just four weeks He's ranking each adaptogen by strength of clinical evidence, walking through the mechanisms, exact dosing, who it's for, who it's not for, and the brands that actually test their products. Your adrenals aren't broken. They just need the right support. This episode gives you the clinical roadmap to get there. Timestamps: 0:00 - Introduction 2:15 - What's actually wrong (HPA axis explained)  4:30 - #5 Siberian Ginseng (Soviet secret weapon)  7:45 - #4 Holy Basil (the Queen of Herbs)  11:30 - #3 Korean Red Ginseng (results in 2 hours)  15:00 - #2 Rhodiola (the burnout fix)  19:30 - #1 Ashwagandha (king of adaptogens)  23:00 - Ashwagandha flatness warning (who should skip it)  26:30 - Exact dosing & best brands for each  28:45 - Dr. G's personal stack Learn more about your ad choices. Visit megaphone.fm/adchoices

My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Host: Brian P. McDonough, MD, FAAFP Guest: Tara Graff, DO, MS Guest: Surbhi Sidana, MD While BCMA-directed CAR T-cell therapy has changed the treatment landscape for patients with relapsed and refractory (R/R) multiple myeloma, access remains uneven outside academic centers. In this expert-led discussion, Dr. Brian McDonough, Dr. Surbhi Sidana, and Dr. Tara Graff explore real-world barriers to referral and delivery, evolving care models, and the multidisciplinary coordination required to extend CAR T therapy into community practice. Dr. Sidana is an Associate Professor of Medicine, and she leads the Myeloma CAR T and Immunotherapy program at Stanford Medicine. Dr. Graff is the Director of Clinical Research at Mission Cancer + Blood, and she serves on the National CAR T-Cell Advisory Board for Multiple Myeloma.

My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Hannah's LinkedIn: https://www.linkedin.com/in/hannahkempski/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Dr. Josh introduces his journey, clinical background, global summit, and the scientific evidence behind Alzheimer's prevention and reversal. #AlzheimersHope #ReversalEvidence #BrainHealth #NeuroWellness

Send us a textDo Heterogeneous Treatment Effects Exist?For the last 50 years, we've designed cars to be safe...For the 50th-percentile male.Well, that's actually not 100% correct.According to Stanford's report, we introduced "female" crash test dummies in the 1960s, but...They were just scaled-down versions of male dummies and...Represented the 5th percentile of females in terms of body size and mass (aka the smallest 5% of women in the general population).These dummies also did not take into account female-typical injury tolerance, biomechanics, spinal alignment, and more.But...Does it matter for actual safety?In the episode, we cover:- Do heterogeneous treatment effects (different effects in different contexts) exist?- If so, can we actually detect them?- Is it more ethical to look for heterogeneous treatment effects or rather look at global averages?Video version available on the Youtube: https://youtu.be/V801RQTBpp4Recorded on Nov 12, 2025 in Malaga, Spain.------------------------------------------------------------------------------------------------------About RichardProfessor Richard Hahn, PhD, is a professor of statistics at Arizona State University (ASU). He develops novel statistical methods for analyzing data arising from the social sciences, including psychology, economics, education, and business. His current focus revolves around causal inference using regression tree models, as well as foundational issues in Bayesian statistics.Connect with Richard:- Richard on LinkedIn: https://www.linkedin.com/in/richard-hahn-a1096050/About StephenStephen Senn, PhD, is a statistician and consultant who specializes in drug development clinical trials. He is a former Group Head at Ciba-Geigy and has taught at the University of Glasgow and University College London (UCL). He is the author of "Statistical Issues in Drug Development," "Crossover Trials in Clinical Research," and "Dicing with Death."Connect with Stephen:- Stephen on LinkedIn: Support the showCausal Bandits PodcastCausal AI || Causal Machine Learning || Causal Inference & DiscoveryWeb: https://causalbanditspodcast.comConnect on LinkedIn: https://www.linkedin.com/in/aleksandermolak/Join Causal Python Weekly: https://causalpython.io The Causal Book: https://amzn.to/3QhsRz4

My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Dr. Chris Goss (Medicine, Pediatrics; Associate Dean for Clinical Research) discusses ways faculty can partner with industry to fund clinical research, serving their patients with cutting-edge science. Dr. Goss recommends working with your department and the UW Clinical Trials Office who can help with the entire study process including conversations with industry partners, IRB questions, and site-specific resources. He walks through the timeline and responsibilities involved with being a principal investigator in a clinical trial and provides tips for how to be successful amidst common bottlenecks and challenges. Clinical research at UW has grown significantly and may be an excellent pathway for faculty looking to diversify their research funding.Learn about the UW Clinical Trials Office here.Music by Kevin MacLeod (https://incompetech.com/)

My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Jaime's LinkedIn: https://www.linkedin.com/in/jaime-valles-2a1728221/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Carla's LinkedIn: https://www.linkedin.com/in/carla-vera-navas-9b5a2439/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

In this episode, host Jeremy Schrand welcomes Tim Schroeder, Founder & CEO of CTI, Jaqueline Aguiar, Managing Director of APAC/LATAM, and Dr. Ludwig Baumann, Global Regulatory Strategist, for an in-depth conversation about the Asia Pacific region's growing impact on clinical research. Together, they explore how population diversity, regulatory innovation, and advanced therapies are shaping the future of clinical trials. The discussion highlights real-world examples, regional strategies, and the evolving role of technology and local expertise in bringing new therapies to patients worldwide.01:33 Welcome to the guests and setting the stage for the discussion.01:50 Key drivers behind Asia Pacific's growth: globalization of research, population scale, rare disease focus, and the need for global market access.03:04 Panelists discuss the region's diversity, infrastructure maturation, and regulatory harmonization efforts (ASEAN guidelines, mutual recognition).05:10 Addressing past concerns about research qualityin Asia Pacific and how they've been resolved.06:15 CTI's strategic expansion into Asia Pacific:doubling of work, global footprint, and real-world examples from COVID-19 vaccine trials in Singapore and Vietnam.08:17 Operational hurdles: regulatory fragmentation, cultural and language diversity, and government investment in science and digital health.10:10 Managing regulatory variability: importance of local expertise, adapting to evolving guidelines, and leveraging relationships with regulators.12:10 Harmonization and efficiency: Singapore's reliance model, Australia's streamlined processes, and their influence as regional role models.14:26 Decentralized and virtual trials post-COVID: remote monitoring, reasons for choosing Australia (speed, tax credits) vs. China (population, cost).16:07 Executing complex, multi-country trials: pivotal registration studies, remote monitoring, and the importance of experienced investigators.18:05 Readiness for advanced therapies: academic medical centers' preparedness, regulatory interest in cell and gene therapy, and the need for in-depth preparation for combination products.20:27 Regulatory flexibility: pre-meetings with authorities, addressing language barriers, and successful integration of Asia Pacific into global trials.22:01 Talent acquisition and retention: strategies for building consistent, high-quality teams across diverse countries.23:53 Patient recruitment: cultural nuances and ensuring data quality and patient retention.26:09 Looking ahead: the impact of AI, harmonization, and infrastructure development on accelerating clinical trial execution in Asia Pacific.28:13 Recent success story: FDA approval of a rare disease drug with global patient participation, highlighting Asia Pacific's role.29:05 Closing thoughts: Asia Pacific's leadership in innovation, regulatory adaptation, and inclusion of rare patient populations.

Denali's LinkedIn: https://www.linkedin.com/in/denalirose/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

The USDA and HHS just released new Dietary Guidelines for Americans. We dig into the new guidelines with Dr. Leigh Frame, our favorite nutrition scientist, co-host of the pod, and co-director of the Frame-Corr Lab here at George Washington University School of Medicine & Health Sciences. An Associate Professor in the departments of Clinical Research & Leadership and Physician Assistant Studies, Leigh combines nutrition and immunity through translational research, leveraging extensive experience in biomedical research and education. Dr. Frame earned her PhD in Human Nutrition and MHS in Immunology from the Johns Hopkins Bloomberg School of Public Health and graduated with Distinction in Biochemistry from Mary Baldwin College. An expert on Integrative Medicine and the gut microbiome, she's also the Executive Director of the GW Office of Integrative Medicine & Health. ◘ Related Links: New Food Guidelines for Americans, https://realfood.gov/; Harvard Healthy Eating Plate, https://nutritionsource.hsph.harvard.edu/healthy-eating-plate/; Dr. Frame's Nutrition Guide, https://rwc.smhs.gwu.edu/nutrition-guide; Canada's Food Guide, https://food-guide.canada.ca/en/ ◘ Transcript bit.ly/3JoA2mz ◘ This podcast features the song “Follow Your Dreams” (freemusicarchive.org/music/Scott_Ho…ur_Dreams_1918) by Scott Holmes, available under a Creative Commons Attribution-Noncommercial (01https://creativecommons.org/licenses/by-nc/4.0/) license. ◘ Disclaimer: The content and information shared in GW Integrative Medicine is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in GW Integrative Medicine represent the opinions of the host(s) and their guest(s). For medical advice, diagnosis, and/or treatment, please consult a medical professional.

Faisal's LinkedIn: https://www.linkedin.com/in/akhtarfaisal/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

In today's show, the art piece "Tornado Town" is looking for a new space after spending time touring the region, and 40 Arkansas students enrolling at UAMS will have all tuition and fees paid for the length of their program this fall. 

My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Noninterventional studies in clinical research are underutilized in clinical research and inefficient. Dan Drozd, CMO of PicnicHealth, knows we can do better. With host Deborah Borfitz, Drozd discusses the issues and ramifications researchers face from the lack of noninterventional studies, offers tactics for raising the bar for evidence generation, and shares what he expects in the clinical research space in 2026 in this episode of the Scope of Things. Plus, Borfitz shares the latest news on an expanding good pharma score card, an entirely telehealth-based cancer trial, a novel online platform for bowel cancer research, improving patient-reported outcomes in cancer trials, a virtual clinical trial for psychedelics, and identifying Type 1 diabetes in the symptom-less window stage. Show Notes   News Roundup Good Pharma Scorecard Study in JAMA Internal Medicine News on the Yale Scool of Medicine website  Nationwide telehealth trial for cancer News on The Ohio State University website Online platform for bowel cancer research News on the Newcastle University website Patient-reported outcomes in cancer clinical trials Paper in The Lancet Oncology News on the European Organisation for Research and Treatment of Cancer website Virtual clinical trial of psychedelics Research article in Advanced Science Type 1 diabetes risk prediction testing Study in The Lancet News on the University of Exeter website Guest Dan Drozd, M.D., CMO of PicnicHealth The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Dr. Elena Gross is a neuroscientist, PhD in clinical research and most importantly - a former chronic migraineur. The lack of tolerable and efficacious treatment options for migraine led her to pursue a MSc in Neuroscience at the University of Oxford and a PhD in Clinical Research at the University of Basel, with the goal of having a better understanding of this common and debilitating disease and ultimately improving clinical care. I am particularly passionate about the therapeutic benefits of ketosis and other nutritional interventions, the role of mitochondrial functioning and energy metabolism in brain health & neurological diseases (particularly migraine), as well as increasing our health span via disease prevention. She is the inventor of four patents, founder & CEO of KetoSwiss and Brain Ritual. Her migraine research papers have been published in high-ranking journals. Disclaimer: None of what we talk about is to be considered medical advice, everything is personal experience only. Please discuss with your medical professional before making any changes concerning your health, diet, or products used. Book: How to Master Migraine https://amzn.to/4i34ZN6 Brain Food: www.brainritual.com https://www.brainritual.com/hackmyage $30 off   Contact Dr. Elena Gross: @drelenagross  @brainritual  Email: info@brainritual.com Give thanks to our sponsors: Try Vitali skincare. 20% off with code ZORA here - https://vitaliskincare.com Get Primeadine spermidine by Oxford Healthspan. 15% discount with code ZORA ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - http://oxfordhealthspan.com/discount/ZORA Get Mitopure Urolithin A by Timeline. 20% discount with code ZORA at https://timeline.com/zora Try Suji to improve muscle 10% off with code ZORA at TrySuji.com - https://trysuji.com Try OneSkin skincare with code ZORA for 15% off https://oneskin.pxf.io/c/3974954/2885171/31050   Join the Hack My Age community on: YouTube: https://youtube.com/@hackmyage Facebook Page: ⁠⁠⁠⁠⁠@⁠Hack My Age⁠     Facebook Group: ⁠⁠⁠⁠⁠⁠@⁠Biohacking Menopause⁠⁠⁠⁠⁠⁠ ⁠   Biohacking Menopause Private Women's Only Support Group: https://hackmyage.com/biohacking-menopause-membership/ Instagram: ⁠⁠⁠⁠⁠@⁠HackMyAge⁠    Website: ⁠⁠⁠⁠⁠⁠HackMyAge.com⁠    For partnership inquiries: https://www.category3.ca/  For transparency: Some episodes of Hack My Age are supported by partners whose products or services may be discussed during the show. The host may receive compensation or earn a minor commission if you purchase through affiliate links at no extra cost to you. All opinions shared are those of the host and guests, based on personal experience and research, and do not necessarily represent the views of any sponsor. Sponsorships do not imply medical endorsement or approval by any healthcare provider featured on this podcast.  

Bipolar depression and mixed episodes remain among the most difficult—and highest-risk—conditions in psychiatry. Even when mood symptoms improve, many patients continue to experience significant cognitive and functional impairment.On NYU Insights on Psychiatry, Dan Iosifescu, MD, explains why standard treatment approaches so often fall short. Dr. Iosifescu argues that symptom suppression is frequently mistaken for recovery, that short-term improvement does not equal durable treatment, and that bipolar mixed episodes expose the limits of one-size-fits-all care.The discussion focuses on the clinical dangers of mixed episodes, the challenge of recognizing them, and the importance of acute stabilization followed by a deliberate transition to sustainable long-term treatment. Dr. Iosifescu also explores how emerging biological research—including metabolic interventions and personalized experimental models—may eventually help clinicians better match patients to treatments.Rather than offering quick fixes, this conversation reframes how clinicians think about success, recovery, and personalization in the treatment of bipolar depression.Guest: Dan Iosifescu, MD, Director of Clinical Research at the Nathan Kline Institute and Director of the Mood Disorders Clinical and Research Program at NYU Langone Health.Watch Insights on Psychiatry on YouTubeSenior Producer: Jon Earle

Send us a textJavonte Maynor joins Dr. Erich Schramm to talk about Mr. Maynor's journey from Division I basketball to starting and running a clinical research site. The entrepreneur talks about his passion for clinical research, representation, and how historically low representation of minorities is a design choice which can be remedied. The duo discusses methods of increasing diversity, trust, and good patient outcomes and how those three ideas are intrinsically linked. They finish the conversation by talking about a shared interest, medical cannabis and the slow movement towards more natural medicines.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Host Mikalyn DeFoor, MD Guest interviewee Matthew T. Provencher, MD, MBA, FAAOS, CAPT, MC, USNR (Ret),discussing his review article, "Advancement in Care Through Applied Translational and Clinical Research in Anterior Shoulder Instability: Military Contribution Over 25 Years: Kappa Delta Award" from the December 1, 2025 issue (https://journals.lww.com/Jaaos/toc/2025/12010) Article summarized from the December 1, 2025 issue (https://journals.lww.com/Jaaos/toc/2025/12010) Review article "2025 Arnold Caplan Award RECLAIM: A Translational Platform for Cartilage Repair and Musculoskeletal Tissue Regeneration Using Allogeneic MSCs" Articles summarized from the December 15, 2025 issue (https://journals.lww.com/Jaaos/toc/2025/12150) Research article "Comparing Fixation Techniques in Metacarpal Fractures: Intramedullary Screw Versus Open Reduction Internal Fixation With Plate and Screw Construct" Follow this link to download these and other articles from the December 1, 2025 issue of JAAOS (https://journals.lww.com/Jaaos/toc/2025/12010) and the December 15, 2025 issue of JAAOS (https://journals.lww.com/Jaaos/toc/2025/12150). The JAAOS Unplugged podcast series is brought to you by the Journal of the American Academy of Orthopaedic Surgeons and the AAOS Resident Assembly.

Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Founder Lulu Ge turned personal pain into purpose with Elix, an herbal wellness brand rooted in Chinese medicine with 90% repeat customers.For more on Elix and show notes click here Subscribe and watch Shopify Masters on YouTube!Sign up for your FREE Shopify Trial here.

In this episode, Carsten Bick shares his path from building healthcare services businesses to leading PhaseWell Research. He reflects on what drew him to clinical research, the opportunity to expand patient and physician access in a fragmented industry, and why people remain central to creating a successful platform. Carsten discusses scaling clinical trials through thoughtful partnerships, why culture and trust matter as much as process and technology, and how Shore Capital's people-first approach aligned with his vision for long-term growth. He underscores the responsibility of building alongside experienced founders, staying close to patients, and letting purpose guide PhaseWell's strategy and leadership.Key Takeaways:People-first leadership comes first, shaping how teams are built, decisions are made, and care is delivered throughout the organization.Expanding access to clinical research requires engaging more physicians and patients in a highly fragmented industry.Trust, culture, and experienced partnerships enable growth while preserving quality, integrity, and alignment with mission.Long-term success is driven by staying close to purpose, investing in people, and building platforms alongside partners who share a long-term vision.Chapters:00:00 - Introduction05:57 - Expanding Access in a Fragmented Industry17:17 - People-First Leadership20:27 - Building Trust Through the Right Partnerships24:57 - Purpose, Scale, and Long-Term GrowthListen to our podcasts at:https://www.shorecp.university/podcastsYou'll also find other Microcap Moments episodes, alongside our series Everyday Heroes and Bigger. Stronger. Faster., highlighting the people and stories that make the microcap space unique.Other ways to connect:Blog: https://www.shorecp.university/blogShore University: https://www.shorecp.university/Shore Capital Partners: https://www.shorecp.com/LinkedIn: https://www.linkedin.com/company/shore-universityThis podcast is the property of Shore Capital Partners LLC. None of the content herein is investment advice, an offer of investment advisory services, or a recommendation or offer relating to any security. See the “Terms of Use” page on the Shore Capital website for other important information.

In this episode, Carsten Bick shares his path from building healthcare services businesses to leading PhaseWell Research. He reflects on what drew him to clinical research, the opportunity to expand patient and physician access in a fragmented industry, and why people remain central to creating a successful platform. Carsten discusses scaling clinical trials through thoughtful partnerships, why culture and trust matter as much as process and technology, and how Shore Capital's people-first approach aligned with his vision for long-term growth. He underscores the responsibility of building alongside experienced founders, staying close to patients, and letting purpose guide PhaseWell's strategy and leadership.Key Takeaways:People-first leadership comes first, shaping how teams are built, decisions are made, and care is delivered throughout the organization.Expanding access to clinical research requires engaging more physicians and patients in a highly fragmented industry.Trust, culture, and experienced partnerships enable growth while preserving quality, integrity, and alignment with mission.Long-term success is driven by staying close to purpose, investing in people, and building platforms alongside partners who share a long-term vision.Chapters:00:00 - Introduction05:57 - Expanding Access in a Fragmented Industry17:17 - People-First Leadership20:27 - Building Trust Through the Right Partnerships24:57 - Purpose, Scale, and Long-Term GrowthListen to our podcasts at:https://www.shorecp.university/podcastsYou'll also find other Microcap Moments episodes, alongside our series Everyday Heroes and Bigger. Stronger. Faster., highlighting the people and stories that make the microcap space unique.Other ways to connect:Blog: https://www.shorecp.university/blogShore University: https://www.shorecp.university/Shore Capital Partners: https://www.shorecp.com/LinkedIn: https://www.linkedin.com/company/shore-universityThis podcast is the property of Shore Capital Partners LLC. None of the content herein is investment advice, an offer of investment advisory services, or a recommendation or offer relating to any security. See the “Terms of Use” page on the Shore Capital website for other important information.

The Big Unlock · Gregory Goldmacher, M.D., Associate Vice President in Clinical Research, and Head of Clinical Imaging & Pathology, Merck Research Laboratories In this episode, Dr. Greg Goldmacher, Associate VP of Clinical Research at Merck, known as MSD outside of the United States and Canada, explains how AI is transforming imaging, clinical trials, and early-stage drug development. Greg describes endpoints as the core of every clinical trial, since they determine whether a therapy is safe or effective. He notes that AI is not new to imaging and aligns well with pattern recognition, yet its real value lies in identifying details that humans often miss. Greg stresses that drug development still depends on huge volumes of data spread across legacy systems. Without strong data standardization, AI cannot deliver reliable results. He also points to the FDA's evolving guidance on AI and emphasizes the need for rigorous validation before using AI-derived measurements for regulatory decisions. Greg highlights the opportunity to improve efficiency, reduce human burden, and generate more consistent insights. With thoughtful adoption, AI can support better decisions in clinical development and improve outcomes for patients. Take a listen.

Explore how residents balance the operating room with clinical research. This episode covers why research matters, how to start, and how it enhances evidence-based practice.Host: Aleksandar Jovanović, MD (Serbia)Guests:Lynn Jeffers, MD, MBA, FACSJustin M. Sacks MD MBA FACSHelen Xun, MD

Show Links:https://pendulumlife.com/How Insulin WorksChapters 00:00 Understanding the Microbiome and Its Impact on Health12:05 The Role of Acromansia in Gut Health30:13 Clinical Insights and Research on Probiotics44:15 Addressing Autoimmunity and Metabolic Health56:27 Practical Applications and Recommendations for Probiotics  To learn more about Mission 22's impact and programs, visit www.mission22.org or find us on social media. IG: @mission_22. Tiktok: @_mission22

On this Make A Difference Minute, Catharine Grimes, President of the Bristol Myers Squibb Foundation, shares how the Foundation's investment in the Winn Awards program has grown into a national effort to expand access to clinical research, build trust in communities, and improve health outcomes for patients across the country. Sponsor: CoraNation Tailoring & Alterations

We kicked off the program with four news stories and different guests on the stories we think you need to know about! 70th Anniversary of Globe Santa! What the program does each year for thousands of children.Guest: Linda Matchan – Boston Globe correspondent - the writer and editor for Globe Santa Big Brothers Big Sisters of Central Mass & Metrowest hit a big milestone this year making more new matches so far this school year than in the previous 10 years (180 matches)! What makes the program so important.Guest: Connie Askin - CEO of Big Brothers Big Sisters of Central Mass & MetroWest American Lung Association Urges Flu Vaccination Following Most Severe Flu Season in Over a DecadeGuest: Dr. David Hill – Pulmonologist, Director of Clinical Research at Waterbury Pulmonary Associates and Volunteer Medical Spokesperson for the American Lung Association CDC drops newborn Hepatitis B recommendation, leaving parents with conflicting guidance…Guest: Charles Hannum, MD, General Pediatrician at Tufts Medical Center See omnystudio.com/listener for privacy information.

Feeling tired and washed out? It could be more than fatigue. Lori Hartwell and Dr. Todd Minga, Vice-President of Clinical Research and Medical Affairs at Akebia Therapeutics uncover how anemia and kidney disease intertwine"and why understanding this hidden link could change how you manage your health.

In this episode, Dr. Zanotti discusses the role of Procalcitonin in the ICU. He is joined by Dr. Simran Gupta, an infectious disease specialist at Brigham & Women's Hospital in Boston. Dr. Gupta has additional training in Clinical Research, Transplant, and Infectious Disease. She recently published an article on reassessing the role of Procalcitonin in critically ill patients with sepsis. Additional resources: Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients with Sepsis: Lessons from the ADAPT-Sepsis Trial. S. Gupta, et al. Clinical Infectious Disease 2025: https://pubmed.ncbi.nlm.nih.gov/40579227/ Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial. JAMA 2025: https://pubmed.ncbi.nlm.nih.gov/39652885/ Procalcitonin-guided antibiotic therapy may shorten the length of treatment and may improve survival- a systematic review and meta-analysis. M Papp, et al. Crit Care 2023: https://pubmed.ncbi.nlm.nih.gov/37833778/ Books and entertainment mentioned in this episode: Shantaram: A Novel. By Gregory David Roberts: https://bit.ly/4ovVHKX SHANTARAM – Apple TV series: https://tv.apple.com/us/show/shantaram/umc.cmc.atxsrive40xli3zh3uxjimut

Dr. Ralf Jeutter discusses the foundational principles of Hahnemannian homeopathy. He emphasizes the importance of observing patients' unique experiences and symptoms, rather than categorizing diseases or personalities, highlighting Hahnemann's focus on phenomenology. Dr. Jeutter also explores common misconceptions in interpreting the Organon, particularly around mental and emotional symptoms, and stresses that remedies should be understood through careful study of provings and original texts. He cautions against oversimplifying remedies into psychological types, which can obscure the depth of each patient's experience. Throughout the conversation, he encourages a return to the core principles of homeopathy, combining attentive clinical observation with a thorough understanding of the remedies. Episode Highlights: 03:56 - Ralf's Journey into Homeopathy 09:45 - Accessing German Texts and the Organon 11:17 - Misconceptions in Interpreting the Organon 18:00 - What are we supposed to do in a homeopathic consultation 19:33 - Understanding the Altered State in Homeopathy 24:06 - Differences Between Hahnemannian and Kentian Homeopathy 28:59 - The Role of Mental Symptoms 30:17 - The Balance Between Psychological and Physical Symptoms 33:34 - What Truly Never Changed in Hahnemann's Homeopathy 41:43 - A Radical Shift in How We Understand Disease 49:57 - Re-examining the Syphilis Model 57:12 - When Everything Is Called Homeopathy 01:02:59 - Why Studying Hahnemann Still Matters 01:08:22 - Where Did Succussion Really Come From About my Guests: Dr. Ralf Jeutter has been involved in homeopathy for over 20 years and is an international teacher and practitioner. He qualified in homeopathy in 2000 from the North-West College of Homeopathy in the UK and continued his medical and homeopathic training at the Institute of Clinical Research in Bombay and Pune, India. He is medically trained in Podiatric Medicine and holds a Ph.D. in Literature and Philosophy. Dr. Jeutter is a former Director of the Society of Homeopaths, the largest homeopathic membership organisation in the UK. Dr. Jeutter is Head of Academic Affairs and Head of Philosophy at the Centre for Homeopathic Education (CHE) in New York and teaches homeopathy internationally, including in London, Budapest, and New York. For over 10 years, he has been involved in the Materia Medica Pura Project initiated and led by Dr. André Saine. His professional focus is on Hahnemannian homeopathy, comparative materia medica, repertory work, and a solid understanding of the foundations and philosophy of Hahnemann and his followers. To learn more about his masterclass on male health issues https://www.cheonline.co.uk/male-health-issues To learn more of his provings https://hpathy.com/ If you would like to support the Homeopathy Hangout Podcast, please consider making a donation by visiting www.EugenieKruger.com and click the DONATE button at the top of the site. Every donation about $10 will receive a shout-out on a future episode. Join my Homeopathy Hangout Podcast Facebook community here: https://www.facebook.com/groups/HelloHomies Follow me on Instagram https://www.instagram.com/eugeniekrugerhomeopathy/ Here is the link to my free 30-minute Homeopathy@Home online course: https://www.youtube.com/watch?v=vqBUpxO4pZQ&t=438s Upon completion of the course - and if you live in Australia - you can join my Facebook group for free acute advice (you'll need to answer a couple of questions about the course upon request to join): www.facebook.com/groups/eughom

  Fertility Docs Uncensored is hosted by Dr. Carrie Bedient from the Fertility Center of Las Vegas, Dr. Susan Hudson from Texas Fertility Center, and Dr. Abby Eblen from Nashville Fertility Center. Today, they had a special Guest: Phillip Romanski, Associate Research Director of US Fertility. He is also an Assistant Professor and Associate Program Director of the reproductive endocrinology fellowship at Mount Sinai. In this episode, the docs explore how research shapes the future of fertility care. As Associate Research Director for US Fertility, Dr. Romanski shares how the organization leverages its extensive national data to support studies that directly influence patient outcomes. With eight to nine active clinical studies, patients can visit the US Fertility website to learn about current opportunities to participate, helping advance science, even if the immediate benefits are for future patients. Dr. Romanski highlights a recent study examining development in embryos that initially appeared to have abnormal fertilization. Surprisingly, many of these embryos progressed to the blastocyst stage, and a significant number were genetically normal. This information may help increase the number of viable embryos for future transfer. He also discusses a recent study with unexpected results: a comparison of fertilization outcomes between ICSI and conventional insemination with frozen sperm. Traditionally, eggs are fertilized with ICSI when using frozen sperm. By dividing eggs from individual patients and comparing ICSI with conventional insemination, the team found no difference in fertilization outcomes. This finding could reduce unnecessary embryo manipulation, minimize risk, and decrease costs for patients. This episode takes a fascinating look at how research today is improving the fertility treatments of tomorrow. This podcast was sponsored by US Fertility.